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Abstract
Background: Chikungunya virus (CHIKV) is a widespread mosquito-borne virus representing a serious challenge to
public health. The largest outbreak in the Middle-East was recorded in 2016–2017 in Pakistan. Sistan and Baluchistan
Province of Iran shares a wide border with Pakistan; accordingly, introduction of CHIKV from Pakistan to Iran seems to
be probable. The current study is aimed at investigating CHIKV infection in Sistan and Baluchistan Province.
Methods: Between April 2017 and June 2018, a total of 159 serum samples of CHIK suspected cases from 10 cities of
Sistan and Baluchistan Province were tested by molecular and serological assays. Samples obtained up to 4 days after
onset of illness were tested by real time PCR (n = 8). Samples collected 5–10 days after disease onset were subjected to
ELISA, as well as real time PCR tests (n = 72). Samples obtained after the 10th day of disease onset were tested by only
ELISA (n = 79). Phylogenetic analysis of real time PCR positive samples was carried out by sequencing of a 1014-bp
region of Envelope 1 gene (E1 gene). Chi-square and independent t tests were used to evaluate the association
between variables and CHIKV infection.
Results: In total, 40 (25.1%) out of 159 samples tested positive either by real time PCR or ELISA tests.Out of 151
samples serologically analyzed, 19 (12.6%) and 28 (18.6%) cases were positive for anti-CHIKV IgM and anti-CHIKV IgG
antibodies, respectively. Of 80 samples tested by real time PCR, CHIKV RNA was detected in 11 (13.7%) sera, all of them
had recent travel history to Pakistan. Additionally, phylogenetic analysis of 5 samples indicated their similarity with
recent isolates of Pakistan outbreak 2016–2017 belonging to Indian Ocean sub-lineage of ECSA genotype. A significant
correlation between abroad travel history and CHIKV infection was observed (P < 0.001). The most common clinical
symptoms included fever, arthralgia/arthritis, myalgia, headache, and chill.
Conclusions: These results present substantial evidence of CHIKV introduction to Iran from Pakistan and emphasize
the need for the enhancement of surveillance system and preventive measures.
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Background
Chikungunya (CHIK) is a worldwide expanding mosquito-
borne infection. Chikungunya virus (CHIKV), an envel-
oped and spherical virus, belongs to Alphavirus genus of
Togaviridae family first detected in 1952 among Makonde
population in Tanzania [1, 2]. CHIKV genome constitutes
of a single strand positive RNA with two open reading
frames (ORFs). The first ORF encodes four nonstructural
proteins (nsP1, nsP2, nsP3, nsP4) and the second one
encodes five structural proteins (capsid [C], and envelope
[E2, E3, 6 k, E1]) [3]. Chikungunya is considered a growing
global health threat as its reemergence in the 2000s led to
widespread epidemics affecting millions of people in more
than 60 countries in Africa, the Americas, Asia, and Eur-
ope [4]. Although the disease is rarely fatal, as its name
implies, it can lead to debilitating arthralgia (in the Ma-
konde language, Chikungunya means “that which bends
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up”) [3].CHIKV is transmitted to humans through in-
fected mosquito bites of Aedes spp., in particular Ae. albo-
pictus and Ae. aegypti. Similar to other arboviruses such
as Dengue and Zika, CHIKV can be transmitted via the
urban transmission cycle between humans and mosquito
[5]. In the majority of infected individuals, there is a four-
to seven-day incubation period prior to onset of disease.
The main symptoms of CHIKV infection are the sudden
onset of high fever (102 °F) and severe arthralgia; other
symptoms include headaches, muscle aches, nausea,
vomiting, arthritis, and skin rash. The clinical signs of the
acute form can be mild, moderate, and severe, but usually
resolve within 3 weeks. About 10–15% of cases develop
chronic forms associated with persistent arthralgia [4, 6].
The first record of CHIKV circulation in the Middle-
East dates back to 1981 in Pakistan [7]. Since then, re-
current outbreaks in Pakistan, Saudi Arabia, and Yemen
are reported in this region [8–11]. The largest out-
breaks in this region leading to over 30,000 infected
cases occurred in 2016–2017 in the Karachi City of
Pakistan [12].
An important factor facilitating the spread of CHIKV
is the increase in international travel, which conse-
quently introduces the virus through viremic travelers
to new regions [3]. If the vectors are present in such
regions, they could acquire the virus, while feeding on
viremic travelers. This subsequently can result in
autochthonous transmission making those areas en-
demic for the disease. Sistan and Baluchistan Province
of Iran shares a border with Pakistan and the residents
of the Southern part of this province have significant
cultural similarities with those of Pakistan and, hence,
constant trade and transport between the two countries
is very common. Consequently, virus introduction from
Pakistan to Iran due to the large incidence of travel is
likely. According to the report on detection of Ae. albo-
pictus in Sistan and Baluchistan Province [13] and the
suitability of this province to establish the mosquitoes
with the potential to transmit CHIKV [14], virus im-
portation via travelers could be a serious health threat.
The current study aimed at investigating the presence
of CHIKV in suspected individuals in Sistan and Ba-
luchistan Province during the outbreak in 2017 in
Pakistan.
Methods
Ethical statement
The current retrospective study was conducted on
samples collected in the context of National Surveillance
Program of Iran for Aedes-borne arboviral infections in
accordance with the protocols approved by Iranian
Centre for Disease Control and Management Com-
mittee. Due to the retrospective nature of the study, it
was not possible to obtain informed consent from the
participants; however, all data were analyzed anonym-
ously and all experiments were carried out according to
the relevant laws and guidelines of the ethical standards
of the Declaration of Helsinki.
Study area
The current cross-sectional study was conducted in
Sistan and Baluchistan Province of Iran. This province,
located in Southeastern Iran with an area of 180,726
km2, is the only province of Iran sharing border with
Pakistan. The climate in this province varies from mod-
erate in North to semi tropical in South. It has the low-
est rainfall from April to November and the southern
part is affected by monsoons, which cause extensive
rainfall and flooding every three to 5 years [15].
Data and sample collection
From April 2017 to June 2018, a total of 159 serum sam-
ples of patients suspected of CHIKV infection (febrile in-
dividuals with arthralgia or arthritis) collected within
Iranian National Surveillance Program from 10 cities
(Fig. 1) including Chabahar, Iranshahr, Konarak, Mirja-
veh, Qasr-e-Qand, Rask, Saravan, Sarbaz, Zabol, and
Zahedan were assessed for CHIKV infection. Demo-
graphic, epidemiologic, clinical, and laboratory data were
collected through questionnaires and patients records.
Laboratory diagnosis
Diagnostic algorithm was determined based on the inter-
val between dates of sampling and onset of disease. In
CHIKV infection, viremia starts before onset of symp-
toms and usually lasts up to 8 days after illness. Anti-
CHIKV antibodies can usually be identifiable in serum
by 5–7 days after onset of symptoms [16]. Therefore,
samples collected up to 4 days after onset of disease
were subjected to molecular test for viral RNA detection
(n = 8). Samples obtained 5–10 days post onset of disease
were tested by serological assays to detect anti-CHIKV
IgM and IgG antibodies, as well as molecular assay (n =
72). Samples collected after the 10th day of disease onset
were analyzed by only serological assays (n = 79). All
CHIKV diagnostic assays were performed at the Depart-
ment of Arboviruses and Viral Hemorrhagic Fevers (Na-
tional Ref. Lab), Pasteur Institute of Iran.
For molecular detection of CHIKV, viral RNA extrac-
tion from serum samples was performed using QIAamp
viral RNA Kit (Qiagen, Germany) according to the
manufacturer’s instruction. The presence of the CHIKV
RNA was evaluated using FTD commercial Dengue/
Chik kit (Fast Track Diagnostics, Luxembourg) based
on qualitative TaqMan real-time PCR. This kit contains
an internal control to ensure the avoidance of false
negative results. For phylogenetic analysis of positive
molecular cases, a 1014-bp region of E1 gene of CHIKV
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genome was amplified by a conventional RT-PCR using
primers Chik-E1-F-10004 (ACAAAACCGTCATC
CCGTCTC) and Chik-E1-R-11138 (TGACTATGTG
GTCCTTCGGAGG) and Qiagen One Step RT-PCR Kit
(Qiagen, Germany) [17]. Each 25 μL of reaction mix-
ture, contained 5 μL 9QIAGEN OneStep RT-PCR Buf-
fer (5x), 0.4 μM of each primer, 10 μL dNTP Mix
(containing 10 mM of each dNTP), 1 μL Enzyme Mix,
0.25 μL(or 1 unit) RNase inhibitor, and 2.5 μL extracted
RNA. The PCR conditions were as follows: reverse
transcription at 50 °C for 30 min, 15 min initial denatur-
ation at 95 °C, 45 cycles including a) denaturation at
95 °C for 30 s, b) annealing at 50 °C for 30 s, and c) ex-
tension at 72 °C for 70 s followed by a final extension at
72 °C for 10 min. The RT-PCR products were elec-
trophoresed on 1% agarose gel containing 0.008% Safe-
Stain (Takapouzist, Iran). RNAs extracted from
confirmed CHKV-positive sample and sterile distilled
water were used as positive and negative controls, re-
spectively. The amplified products were sequenced
using the Sanger method in both directions using
primers Chik-E1-F-10004 and Chik-E1-R-11138. The
raw data of sequencing was trimmed and assembled
using CLC Main Workbench software (CLC bio,
Denmark) followed by confirmation by BLAST (https://
blast.ncbi.nlm.nih.gov/Blast.cgi). Phylogenetic analysis
was performed using MEGA6. For this purpose, the
maximum likelihood methodand the kimura 2-
parameter model were used with 10,000 bootstraps.
Detection of anti-CHIKV IgM/IgG antibodies was
performed using commercial ELISA (enzyme-linked
immunosorbent assay) kit (Euroimmun, Germany) ac-
cording to the manufacturer’s instructions. Based on
the protocol, results were reported as a ratio of the
optical density of each sample to the optical density
of the calibrator in which a ratio of ≤0.8 was consid-
ered negative, a ratio between ≥0.8 and ≤ 1.1 was
considered borderline, and a ratio of > 1.1 was inter-
preted as positive.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 19). The results of the serological and molecular
tests were analyzed positively and negatively and the
Fig. 1 Geographical location of Sistan and Baluchistan Province and sampling areas, 2017 to 2018. This figure was originally created in this study
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borderline results were considered as negative. Chi-
square and independent ttests were used to check the
relationship between variables and CHIKV infection. P-
values less than 0.05 were considered statistically
significant.
Results
According to diagnosis algorithm, eight samples were
tested only by molecular assay (category 1), 79 samples
were analyzed by only serological assay (category 2), and
72 samples were investigated by both molecular and
serological assays (category 3).
Of the 151 samples (category 2, 3) serologically ana-
lyzed for anti-CHIKV IgM/G antibodies, 12 (7.9%) were
borderline, and 19 (12.6%) were positive for anti-
CHIKV IgM; and 28 (18.6%) cases were positive for anti-
CHIKV IgG.
Molecular analysis of 80 (category 1, 3) serum samples
showed presence of the CHIKV RNA in 11 (13.7%) sera;
all of them were negative for dengue virus. Among
CHIKV RNA positive samples, five were successfully se-
quenced. The obtained sequences were submitted to the
GenBank as Iran-5947 (gi: MH746782), Iran-6049 (gi:
MH746783), Iran-6051 (gi: MH746784), Iran-6062 (gi:
MH746785), and Iran-5300 (gi: MK775711). In the
phylogenic tree, these sequences clustered with recent
isolates of Pakistan outbreak 2016–2017 belonging to In-
dian Ocean sub-lineage of ECSA (East/Central/South
African) genotype (Fig. 2). The strains Iran-5947, Iran-
6049, and Iran-6051 were identical to strains of the re-
cent outbreak in Pakistan (MF740875- MF740881) [18].
Iran-6062 strain showed one new amino acid substitu-
tion of I/T nonpolar hydrophobic amino acid, isoleucine,
to polar amino acid, threonine, at position 3593 amino
acid residue (10,847 nt, ATT/ACT) compared with
Pakistan 206–2017 strains [18]. Also, Iran-5300 strain
showed a rare non-synonymous substitution T/C at nu-
cleotide 10,560, which was observed in Asian Caribbean
strain (KC488650). In addition, four known mutations
including K211E, M269 V, D284E, and V322A were ob-
served in all identified strains.
These data showed high similarity between strains
detected in the current study (Iran-6051, Iran 6049,
Iran-5947, Iran-6062 and Iran-5300) and strains identi-
fied during the Pakistan outbreak of 2016–2017.
Overall, from 159 samples assessed for CHIKV infec-
tion (by both serological and molecular assays), 40 cases
(25.1%) were positive. The majority of positive cases
(65%) were residents of Sarbaz. As shown in Table 1,
there was a significant correlation between abroad travel
history and CHIKV infection (P < 0.001). All CHIKV
positive cases had a history of traveling abroad and
molecularly-tested positive cases had a recent travel his-
tory (less than 2 weeks prior to the date of sample
collection) to Pakistan. In addition to fever and arthral-
gia/arthritis, myalgia, headache, and chill were the most
common clinical symptoms. Most of infected cases were
identified in spring (47.5%) and summer (20%) (P =
0.042).
Discussion
CHIK is considered as a global health threat due to the
factors associated with its geographical expansion in-
cluding global warming/climate change, globalization
with significant increase in international travels, and
adaptation of virus to new vectors [1, 2]. Extensive epi-
demics in Asia and Africa could be a potential risk for
its spread to other non-endemic countries in the world,
particularly the ones sharing the same climate or border-
ing other countries that mosquito vectors already colo-
nized or could be colonized [19]. In the current study,
out of 159 patients with fever and arthralgia/arthritis in
Sistan and Baluchistan Province, 25.1% were positive for
either viral genome or anti-CHIKV antibodies. Unlike
molecular detection of viral genome, due to possible
cross-reactivity in serological testing, the positive result
in ELISA cannot be concluded as a definitive infection
and should be confirmed by the supplementary
neutralization test [20]. In the current study, CHIKV
genome was detected in sera of 11 patients, in which all
had a recent travel history to Pakistan, where a wide-
spread epidemic of the disease was ongoing at the time
of the current study [21].
The phylogenetic analysis revealed significant similar-
ity between the identified strains in the current study to
those of Pakistan 2017 strains. Consequently, there is lit-
tle doubt that the virus was imported to Iran from the
CHIKV endemic neighboring country of Pakistan. Phylo-
genetically, CHIKV is categorized into three distinct ge-
notypes e.g., West African, ECSA, and Asian [22].
Recently, a descendant lineage of ECSA, i.e., the Indian
Ocean Lineage (IOL) is also identified. This lineage was
responsible for several outbreaks in Southeast Asian
islands from 2005 to 2014 [23, 24]. It is suggested that
evolutionary mutations in different genotypes can affect
the ability of virus in vector adaptation and, hence, its
transmission pattern [25]. In the current study, a new
nonsynonymous mutation in E1 gene (T288I) was ob-
served in the Iran-6062 (MH746785) strain. The E1 pro-
tein is responsible for fusion of the viral envelope and
cellular membrane, which is part of viral entry stage
[26]. Mutations in E1 protein, even in a single residue,
may affect vector specificity of the virus as Tsetsarkin
et al., [25] demonstrated a direct association between
E1-A226V mutation and adaptation of CHIKV to Ae.
albopictus. Accordingly, there is a potential for the mu-
tation found here to be functionally important; however,
this requires further investigations. The study also
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detected CHIKV strains harboring E1-K211E implicated
in facilitating endosomal entry of virus in Ae. Aegypti in
background of E1-226A [27]. Nonetheless, vector com-
petence was not only dependent on viral mutations. It is
suggested that alongside virus genotype, vector genotype
and environmental factors such as temperature also play
a role in virus adaptation to vectors [28, 29].
There are several reports on the importation of arbovi-
ruses such as CHIK by travelers to other countries [19].
In case the vector is present in the destination country,
it is likely that the virus is transmitted to vectors and,
therefore, the disease could become endemic in that
country. The first CHIK outbreak in Italy is a typical ex-
ample of this issue. In 2007, CHIKV was reportedly in-
troduced to Italy by a viremic worker traveling from
India to the Northeast part of the country where Ae.
albopictus mosquitoes were already established [30].
The entomological surveillance conducted alongside
the current study did not find the CHIKV vectors in the
studied areas. However, during a six-year entomological
surveillance in Sistan and Baluchistan Province, adult
Ae. albopictus was detected in Nikshahr and Sarbaz cit-
ies in 2009 and adult and larvae of the same species were
identified in Chabahar in 2013 [13]. This finding
Fig. 2 Phylogenetic tree showing high similarity between strains detected in this study (Iran-6051, Iran 6049, Iran-5947, Iran-6062 and Iran-5300)
and strains identified during the Pakistan outbreak of 2016–2017
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Table 1 Association of CHIKV infection with characteristics of participants, from Sistan and Baluchistan province, southeastern Iran,
2017–2018
Variables Chik. Neg. (n = 119) (%) Chik. Pos. (n = 40) (%) p-value
Gender
Female 57 (73.1) 21 (26.9) 0.584
Male 62 (76.5) 19 (23.5)
Age (Mean ± SD) 31.7 ± 15.3 41.5 ± 16.3 0.001
Epidemiological History
Abroad travelling history, N (%) 21 (17.6) 40 (100) < 0.001
Travel Duration (day) (Mean ± SD) 15.7 ± 16.7 26.83 ± 39.3 0.218
Country with a travel history
Afghanistan 2 (1.7) 0 (0) 0.230
Malaysia 1 (0.8) 0 (0) 0.426
Pakistan 18 (15) 40 (100) 0.001
City of residence
Chabahar 7 (5.9) 4 (10) 0.367
Iranshahr 14 (11.7) 2 (5) 0.224
Konarak 3 (2.5) 0 (0) 0.313
Mirjaveh 2 (1.7) 0 (0) 0.411
Qasr-e Qand 1 (0.8) 0 (0) 0.562
Rask 1 (0.8) 0 (0) 0.562
Saravan 4 (3.4) 0 (0) 0.242
Sarbaz 50 (42) 26 (65) 0.010
Zabol 1 (0.8) 0 (0) 0.562
Zahedan 36 (30.2) 8(20) 0.220
Villager 57 (47.9) 19 (47.5) 0.451
Season of Symptom Onset
Spring 34 (28.6) 19 (47.5) 0.042
Summer 48 (40.3) 8 (20)
Fall 17 (14.3) 0 (0)
Winter 7 (5.9) 2 (5)
Mosquito bite 30 (25.2) 8 (20) 0.096
Clinical signs
Chill 1 (0.8) 7 (17.5) < 0.001
Myalgia 40 (33.6) 20 (50) 0.321
Rash 5 (4.2) 2 (5) 0.646
Headache 34 (28.6) 11 (27.5) 0.020
Conjunctivitis 11 (9.2) 2 (5) 0.064
Retro orbital pain 14 (11.7) 3 (7.5) 0.078
Stomachache 10 (8.4) 3 (7.5) 0.426
Nausea 18 (15.1) 7 (17.5) 0.658
Vomiting 17 (14.3) 7 (17.5) 0.679
Diarrhea 12 (10) 7 (17.5) 0.608
Laboratory findings
Leukopenia 9 (7.5) 2 (5) 0.191
Platelet count(Mean ± SD) 134,486 ± 113,962 131,730 ± 126,948 0.958
WBC count(Mean ± SD) 9940 ± 1720 4980 ± 140) 0.353
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indicated favorable conditions for the establishment of
CHIKV vector in this area. Additionally, modeling stud-
ies using geographic, metrologic, satellite imagery, and
remote sensing data from 2011 to 2015 demonstrated
that this province was vulnerable to entry and establish-
ment of CHIKV vectors, particularly Ae. Albopictus [14,
31]. Therefore, the first and foremost step to prevent
outbreaks of the disease in the country is to block vector
establishment. This can be accomplished by improving
the environmental conditions in order to eliminate the
mosquito breeding sites, and systematic and comprehen-
sive entomological monitoring. Educating and training
people is also a great help to achieve this goal. In
addition to the above measures, it is also important to
monitor patients and identify infected cases in the acute
phase of the disease (when the transmission of the virus
from the patient to the vector is possible). In this regard,
training clinicians and people is essential for rapid iden-
tification of the infected cases [32].
In addition to Pakistan, there are other possible
routes of virus entry to the country. According to the
Department of Arboviruses and Viral Hemorrhagic
Fevers at Pasteur Institute of Iran (National Reference
Laboratory), the first case of CHIK was imported
from India in September 2016 (unpublished data).
Moreover, numerous imported cases of Dengue are
recorded returning from Southeast Asian countries.
Therefore, informing tourists and travelers to endemic
countries to take precautions such as using insect re-
pellents, wearing long-sleeved cloths, and using mos-
quito nets can play a significant role in reducing the
number of infections.
In the current study, 67.5% of positive cases were in-
fected in the spring and summer, when there is an in-
crease in the mosquito activity and reproduction. Most
of the positive cases (65%) were from Sarbaz. This can
be on the account of that the majority of participants
(47.8%) were from this city.
Unlike other arboviral diseases, most of the patients
with CHIK have clinical symptoms [3] and the most
common symptoms include severe fever (above 102 °F),
arthralgia, headache, and muscle pain [5]. These are pre-
dictive symptoms in endemic and epidemic areas [33].
The results of the current study also indicated that to-
gether with joint involvement, headache, and muscle
pain were the most common symptoms. In addition to
clinical symptoms, changes in blood factors such as lym-
phopenia and thrombocytopenia are also helpful for
clinical diagnosis [34]. Nevertheless, these changes are
mild and short compared to other arboviral diseases
such as dengue [35, 36]. In the current study, mild
leukopenia and thrombocytopenia were observed in
positive cases; however, there was no significant differ-
ence between the two groups.
Conclusions
The results of the current study provide evidence of
CHIKV in Iran, which were closely related to the strains
in Pakistan. This highlights the urgent need to enhance
the surveillance system and implement preventive
measures.
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